This site is intended for US Healthcare Professionals.

Open page example

Explore some very short feature overview for open pages

Register to explore our Dyscovery Platform

Example text

The efficacy and safety of Dysport were evaluated in a randomized, prospective, double-blind, multicenter, low-dose controlled, multiple treatment study with pediatric patients aged 2 to 17 with upper limb spasticity (ULS). The study evaluated a total of 208 patients who had a diagnosis of spasticity due to cerebral palsy, were either toxin-naive or non-naive, had a baseline Modified Ashworth Scale (MAS) score of ≥2 in the primary target muscle group (PTMG), and increased muscle tone in at least one upper limb.1,2

The primary efficacy endpoint was mean change from baseline in MAS score in the PTMG at Week 6. Secondary efficacy endpoints were mean change in the Physician Global Assessment (PGA) at Week 6 and mean Goal Attainment Scale (GAS) score at Week 6.1,2

For the first treatment cycle, patients were randomized to receive2:

  • Dysport 2 Units/kg (n=69)
  • Dysport 8 Units/kg (n=69)
  • Dysport 16 Units/kg (n=70)

Patients were reassessed for re-treatment eligibility at Week 16. If ineligible for re-treatment, they were evaluated at every 6 weeks (±2 weeks) until eligible.2

There had to be a minimum of 16 weeks between each injection session, and patients could receive a maximum of 4 sessions over the course of the study. After completing their first treatment cycle, patients receiving Dysport 2 Units/kg were re-randomized to receive Dysport 8 Units/kg or Dysport 16 Units/kg.1,2

Patients receiving the higher doses remained at their dose unless an adjustment up (not exceeding 16 Units/kg) or down was mandated by the investigator. The study remained double-blind for the remaining 3 cycles.2

The PTMG could be changed for the 3 remaining cycles, from elbow to wrist flexors or from wrist to elbow flexors, if the following criteria were met: the MAS score of the new PTMG was higher than the MAS score of the previous PTMG and the new PTMG had a MAS score ≥1.2

Sustained relief beyond the minimum time to re-treatment

For many pediatric patients with ULS, the effect of Dysport lasted beyond the minimum 16-week re-treatment period. A majority did not need re-treatment until Week 16 to 28; some experienced an even longer duration of response.1,2

More information

For many pediatric patients with ULS, the effect of Dysport lasted beyond the minimum 16-week re-treatment period. A majority did not need re-treatment until Week 16 to 28; some experienced an even longer duration of response.1,2

Explore hands on
Explore more here

Explore more here

Get answers

Explore more here

Whats involved?

Explore more here

Example title card
some subtitles
Example title card
some subtitles
Example title card
some subtitles
Example title card
some subtitles
Example title card
some subtitles
Example title card
some subtitles

Important Safety Information

INDICATIONS
DYSPORT (abobotulinumtoxinA) for injection is indicated for the treatment of:
spasticity in patients 2 years of age and older
cervical dystonia in adults

Please see the Dysport full Prescribing Information, including BOXED WARNING.

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of DYSPORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

 

Contraindications
DYSPORT is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow’s milk protein, or to any of the components in the formulation, or infection at the proposed injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a serious reaction occurs, discontinue DYSPORT and institute appropriate medical therapy immediately.

Warnings and Precautions
Lack of Interchangeability Between Botulinum Toxin Products
The potency Units of DYSPORT are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties
Treatment with DYSPORT and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Treatment of cervical dystonia with botulinum toxins may weaken accessory muscles of ventilation, which may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these muscles. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, vCJD, or CJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction
The possibility of an immune reaction when injected intradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for intramuscular injection.

Pre-existing Conditions at the Injection Site
Caution should be exercised when DYSPORT is used where the targeted muscle shows excessive weakness or atrophy.

Adverse Reactions
The most common adverse reactions (≥4%) in adults with upper limb spasticity include muscular weakness; in adults with lower limb spasticity (≥5%) include falls, muscular weakness, and pain in extremity
The most common adverse reactions (≥10%) in pediatric patients with upper limb spasticity include upper respiratory tract infection and pharyngitis; in pediatric patients with lower limb spasticity include nasopharyngitis, cough, and pyrexia
The most common adverse reactions (≥5%) in adults with cervical dystonia include muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders

Drug Interactions
Co-administration of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of DYSPORT may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before and after administration of DYSPORT.

Please see the Dysport full Prescribing Information, including BOXED WARNING.

References:
Dysport®. Prescribing information. Ipsen Biopharmaceuticals; 2023.
Drugs@FDA: FDA-Approved Drugs. US Food and Drug Administration. Accessed February 10, 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125274.
Esquenazi A, Delgado MR, Hauser RA, et al. Duration of symptom relief between injections for abobotulinumtoxinA (Dysport®) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. 2020;11:576117.

 

Terms of Use
Privacy Policy
State Supplement Website Privacy Notice
Consumer Health Data Privacy
Cookies Notices
Contact Us
Your Privacy Choices

Dysport® (abobotulinumtoxinA) for injection, for muscular use 300- and 500-Unit vials.
Dysport is a registered trademark of Ipsen Biopharm Limited.
©2026 Ipsen Biopharmaceuticals, Inc. All rights reserved. November 2026 DYS-US-010624